Drug Trial Radar · NCT05269459
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Dec 1, 2022
Primary completion
Dec 2028
Study completion Apr 2029
Sponsor
- Lead sponsor
- University of NebraskaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ananda Scientific; University of Texas at Austin
- First posted
- Mar 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Post-traumatic stress disorder (PTSD) is a psychiatric disorder than may develop following a traumatic event including serious incidents, natural or human-caused disasters, violence, death of a loved one, receipt of traumatic news, or serious illness/hospitalization. While half of US adults experience trauma in their lifetime, most do not develop PTSD. However, those who do develop the disorder may have significant impairments and risk for functional dysfunction across multiple domains. While short term symptoms are the most common, some individuals develop chronic PTSD. These individuals may experience frightening and intrusive thoughts and memories of the event (flashbacks), have sleep disturbances, feel numb or detached, and be easily startled (hypervigilance). This trial is a double-blind placebo controlled study of cannabidiol (CBD) for symptoms of PTSD in adults using liquid structure Formulation (Nantheia ATL5). Participants complete three weeks of baseline data collection including assessments of activity and sleep. Intervention is Nantheia ATL5 or placebo. Dose is initiated at 400mg BID and maintained over 8 weeks. Standardized symptom profile measurements, clinician assessments, laboratory testing, and suicide screening is completed throughout.
Conditions
- PTSD
Interventions
Cannabidiol Administered as Nantheia ATL5Drug
Participants will take 4 gel capsules twice daily containing 100mg of Nantheia ATL5.
PlaceboDrug
Participants will take 4 matching gel capsules twice daily containing no active drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Post-traumatic Stress Disorder Symptom RatingTime frame: Baseline and 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.